Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Subscribe To Our Newsletter & Stay Updated
